Last reviewed · How we verify
Agrippal
At a glance
| Generic name | Agrippal |
|---|---|
| Sponsor | University of Surrey |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months (PHASE3)
- Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults (PHASE1)
- Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers (PHASE1, PHASE2)
- ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses (PHASE2)
- Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis (PHASE4)
- Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions (PHASE4)
- Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adolescents (PHASE3)
- Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Agrippal CI brief — competitive landscape report
- Agrippal updates RSS · CI watch RSS
- University of Surrey portfolio CI